Table 3.
Prophylaxis of OT recurrences. Overview of registered primary and secondary outcome parameters.
| Reference Number | First Author | Year of Publication | n (Cases) | Country of Origin | Treatment | BCVA | Recurrence Events | Time to Recurrence | Lesion Size | Change in Inflammation | Time to Healing | Safety and Side Effects | Remarks |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| [41,42] | Silveira C | 2002/15 | 124 | Brazil | treatment and recurrence prophylaxis with TMP/SMZ 2×/week over 20 months | − | + | + | − | + | − | + | After 2 years, fewer recurrences in the prophylaxis group. After 10 years, recurrence rate identical in both groups. |
| [55] | Reich M | 2016 | 84 | Germany | 20 different AB regimen +/− steroids | − | + | + | − | − | − | − | time to recurrence not longer after ABs than without therapy, faster recurrence after steroids without AB |
| [56] | Borkowski PK | 2016 | 352 | Poland | treatment and recurrence prophylaxis for 6 months with Pyrimethamine and Sulfadoxine (Fansidar®) | − | + | + | − | − | − | − | Pyrimethamin/Sulfadoxine treatment and prophylaxis for 6 months prevented recurrences over 3.5 years |
| [43,44] | Fernandes-Felix JP | 2016/20 | 141 | Brazil | treatment and recurrence prophylaxis with TMP/SMZ 3×/week for 12 months | + | + | + | − | − | − | − | Effect of TMP/SMZ treatment and prophylaxis over 12 months on recurrences over 5 years |
AB, antibiotics; TMP/SMZ, trimethoprim 800 mg and sulfamethoxazole 160 mg; RCT, randomized clinical trial; OT, ocular toxoplasmosis.